Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.85 USD | +0.25% | -2.76% | -7.20% |
May. 01 | Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts | MT |
May. 01 | Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024 |
Business Summary
Number of employees: 284
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Treatments for B-cell Diseases
100.0
%
| 3 | 100.0 % | 234 | 100.0 % | +8,290.02% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 3 | 100.0 % | 234 | 100.0 % | +8,290.02% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 93-05-17 |
Sean Power
DFI | Director of Finance/CFO | 42 | 11-12-28 |
Jenna A. Bosco
IRC | Investor Relations Contact | - | 11-11-30 |
Adam Waldman
PRN | Corporate Officer/Principal | - | 18-06-03 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 93-05-17 |
Laurence Charney
BRD | Director/Board Member | 76 | 12-02-29 |
Kenneth Hoberman
BRD | Director/Board Member | 59 | 14-12-14 |
Yann Echelard
BRD | Director/Board Member | 60 | 12-11-08 |
Daniel Hume
BRD | Director/Board Member | 57 | 15-03-31 |
Sagar Lonial
BRD | Director/Board Member | 57 | 20-04-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 154,584,254 | 139,779,168 ( 90.42 %) | 41,309 ( 0.0267 %) | 90.42 % |
Company contact information
TG Therapeutics, Inc.
3020 Carrington Mill Boulevard Suite 475
27560, Morrisville
+212 554 4484
http://www.tgtherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.20% | 2.27B | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- TGTX Stock
- Company TG Therapeutics, Inc.